Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#1498 Safety and Efficacy of Pasireotide LAR (PAS) in Patients with Advanced Neuroendocrine Tumors (NET): Findings of a Phase I, Multi-center, Open-label, Dose-escalation Study

Introduction: PAS, a next generation SSA, is investigated to determine the maximum tolerated dose (MTD) in pts with advanced NET.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Yao J, Chan J, Mita A, Kundu M, Valera S,

Keywords: Pasireotide, MTD,

#1224 A Randomized Open-label Phase II Study of Everolimus Alone or in Combination with Pasireotide LAR in Advanced, Progressive Pancreatic Neuroendocrine Tumors (pNET): COOPERATE-2 Trial

Introduction: Pasireotide is a somatostatin analog (SSA) that targets somatostatin receptor subtypes 1-3 and 5. An earlier phase I study showed antitumor activity of everolimus+pasireotide LAR (EVE+PAS) in NET.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Kulke M, Ruszniewski P, Van Cutsem E, Valle J, De Herder W,

Keywords: everolimus, pNET, pasireotide LAR,

#792 Phase II Clinical Trial of Pasireotide LAR in Patients with Metastatic Neuroendocrine Tumors

Introduction: Pasireotide LAR is a novel SSA with avid binding to SSTR 1, 2, 3 and 5. It has never been investigated in treatment naïve patients.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Strosberg J

Authors: Cives M, Kunz P, Nguyen P, Jump H, Vilay K,

Keywords: NET, pasireotide, first-line,

#747 A Single-Center, Open-Label, Phase II, Proof-of-Concept Study with Pasireotide LAR in Patients with Progressive Medullary Thyroid Cancer (MTC): Preliminary Data

Introduction: MTC is a well-differentiated neuroendocrine tumor in which somatostatin receptor (sst) expression is higher for sst1 and sst5 than for sst2. This may explain why the available sst2–selective analogues do not work in these patients and why pasireotide (SOM230), a novel, multi-receptor targeted somatostatin analogue with high-binding affinity for sst1, 2, 3 and sst5 could be effective.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Faggiano A, Ferolla P, Vitale G, Del Prete M, Ramundo V,

Keywords: medullary thyroid cancer, pasireotide, somatostatin receptor,

#678 Management of Patients with Neuroendocrine Tumors: Case Presentations Including Long-term, Open-label Pasireotide

Introduction: The somatostatin analog (SSA) pasireotide long-acting release (pasireotide LAR) is under investigation for the treatment of patients (pts) with NET and carcinoid disease refractory or resistant to available SSA.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author: Wolin E

Authors: Wolin E, Giannone V, Hermasillo Resendiz K,

Keywords: somatostatin analog, pasireotide, carcinoid syndrome,